Research & Development Market Research Reports & Industry Analysis
Bringing R&D costs and times down, therefore, means there are many opportunities to improve efficiencies, advance technological innovation, and economize and optimize. The pharmaceutical R&D category tracks both drug pipeline reports, competitive R&D strategies, and markets important and ancillary to the research efforts themselves, including activities in the biotech and sector that impinge upon the process.
Research & Development Industry Research & Market Reports
-
Marine Biotechnology
... CAGR of 8.4% over the analysis period 2024-2030. Biomaterials, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$6.5 Billion by the end of the analysis period. ... Read More
-
Beta Interferon
... CAGR of 3.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$968.9 Million While China is Forecast to Grow at 4.5% CAGR The Beta Interferon market in the U.S. is estimated at ... Read More
-
Biotechnology
... 8.5% over the analysis period 2024-2030. DNA Sequencing Market, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$33.5 Billion by the end of the analysis period. ... Read More
-
Immune Checkpoint Inhibitors
... at a CAGR of 16.5% over the analysis period 2024-2030. PD-1, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$109.0 Billion by the end of the ... Read More
-
Human Liver Models
... at a CAGR of 9.3% over the analysis period 2024-2030. Drug Discovery, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$225.8 Million by the end of ... Read More
-
Asthma Therapeutics
... CAGR of 2.3% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$10.7 Billion by the end of the analysis ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
White Biotechnology
... CAGR of 7.8% over the analysis period 2024-2030. Biochemicals, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$198.1 Billion by the end of the analysis period. ... Read More
-
Research Antibodies
... CAGR of 4.7% over the analysis period 2024-2030. Reagent, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$5.4 Billion by the end of the analysis period. ... Read More
-
Recombinant DNA Technology
... at a CAGR of 4.5% over the analysis period 2024-2030. Medical, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$77.9 Billion by the end of the ... Read More
-
Healthcare Contract Management Software
... 2030, growing at a CAGR of 19.3% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$7.1 Billion by the end ... Read More
-
Interferon
... 2.8% over the analysis period 2024-2030. Interferon Beta, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth ... Read More
-
Hepatitis C Treatment
... at a CAGR of 10.7% over the analysis period 2024-2030. HCV Protease Inhibitors, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$25.3 Billion by the end ... Read More
-
Bone Marrow Aspirate Concentrates
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Bone Marrow Aspirate Concentrates Systems, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$178.5 ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end of ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Synthetic Protein
... CAGR of 15.7% over the analysis period 2024-2030. The U.S. Market is Estimated at US$87.8 Million While China is Forecast to Grow at 20.2% CAGR The Synthetic Protein market in the U.S. is estimated at ... Read More
-
Soft Tissue Allografts
... at a CAGR of 4.9% over the analysis period 2024-2030. Orthopedic, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.9 Billion by the end of the ... Read More
-
Bone Morphogenetic Proteins
... at a CAGR of 2.4% over the analysis period 2024-2030. Recombinant human bone morphogenetic protein-2 (rhBMP-2), one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$484.6 Million ... Read More
-
Albumin
... 3.8% over the analysis period 2024-2030. Human Serum Albumin, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$902.4 Million by the end of the analysis period. ... Read More
-
Life Science Analytics
... at a CAGR of 13.3% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$44.7 Billion by the end of the ... Read More
-
Stromal Vascular Fraction
... at a CAGR of 4.5% over the analysis period 2024-2030. Isolation Products, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$99.5 Million by the end of ... Read More
-
Protein Fractionation
... CAGR of 5.4% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$24.4 Billion by the end of the analysis period. ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$119.2 Billion by the end of the analysis ... Read More
-
Biotech API Manufacturing Services
... 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. API Process Development & Manufacturing, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$30.2 ... Read More
Research Assistance
